Subjective endpoints, potential bias and conflicts of interest should raise questions about conclusions. Introduction: The production and release of new antibiotics is rare and should be celebrated by clinicians. As antibiotic resistance continues to mount our options narrow and in turn our patients suffer. Recently, the New England Journal of Medicine (NEJM) published two articles … Continue reading Omadacycline, NEJM and Non-Inferiority Studies